| Name | Title | Contact Details |
|---|
LifeLine Financial captains fast-growing businesses nationwide in service, technology, retail, and trades. We offer exceptional bookkeeping and accounting services nationwide. Call us today and grab a LifeLine (603) 782-4663
Since 1902, BIA is recognized by its customers for the quality of its products and services in the mining and quarrying, construction, transport and energy sectors as exclusive distributor of Komatsu equipment and parts, as well as other reputable manufacturers like Metso, Cummins, Bomag, MAN, Foton, Furukawa, GHH… for complementary products. Today BIA Group has become a well-established, multinational and trusted long-term business partner, operating in more than 20 countries in Africa and in the Benelux regions. The family-owned group distinguishes itself through the extent of its network and state-of-the-art technical facilities to support its clients close to their operations. The group is continuously developing its capabilities and expertise to meet the ever-growing customer needs. BIA provides a wide range of solutions including equipment sales, rental, parts supply, aftersales services as well as support services such as structured financing solutions, supply chain management and training to assist its customers on their projects development. More recently, BIA was pioneer in adopting innovation & technology solutions to increase customers productivity and safety on sites.
LTCG is a leading provider of business process outsourcing for the insurance industry. The nations largest insurers rely on our unparalleled expertise to help manage their complex long-term care portfolios and maximize financial performance. We also provide clients with advanced risk management insight built upon our unique and proprietary long-term care underwriting and claims databases. LTCG has more than 1.4 million long-term care policies currently under its management, representing nearly 20% of all active policies. We serve over 50 national carriers, including every one of the top 10 insurers in the long-term care market. Our experienced management team, which has worked together for years, includes some of the most recognized and respected leaders in the long-term care industry. And our information systems have been developed specifically to support the intricacies of this unique market. To learn more, visit www.ltcg.com
CI Financial is an independent company offering global asset management and wealth management advisory services. We are driven by a commitment to provide individuals and institutions with the highest-quality investments and advice—and offer a comprehensive and innovative selection of strategies and services. Our employees are at the heart of everything we do. They must be comfortable in a fast-paced environment in an industry that is always changing. A healthy dose of ambition, a willingness to go the extra mile and a strong sense of camaraderie are what we look for in our team members.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.